Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TT 2 R 2 score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF)

A study protocol

Phrommintikul, Arintaya; Nathisuwan, Surakit; Gunaparn, Siriluck; Krittayaphong, Rungroj; Wongcharoen, Wanwarang; Sehmi, Sukhi; Mehta, Samir; Winkles, Neil; Brocklehurst, Peter; Mathers, Jonathan; Jowett, Sue; Jolly, Kate; Lane, Deirdre; Thomas, G. Neil; Lip, Gregory Y.H.

Published in:
BMJ Open

DOI (link to publication from Publisher):
10.1136/bmjopen-2021-051987

Creative Commons License
CC BY 4.0

Publication date:
2021

Document Version
Publisher's PDF, also known as Version of record

Link to publication from Aalborg University

Citation for published version (APA):
Phrommintikul, A., Nathisuwan, S., Gunaparn, S., Krittayaphong, R., Wongcharoen, W., Sehmi, S., Mehta, S., Winkles, N., Brocklehurst, P., Mathers, J., Jowett, S., Jolly, K., Lane, D., Thomas, G. N., & Lip, G. Y. H. (2021). Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TT 2 R 2 score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): A study protocol. BMJ Open, 11(10), Article e051987. https://doi.org/10.1136/bmjopen-2021-051987
Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TT$_2$R$_2$ score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol

ArinTaya Phrommintikul $^{1,2}$, Surakit Nathisuwan $^3$, Sirluck Gunaparn $^1$, Rungroj Krittayaphong $^4$, Wanwarang Wongcharoen $^1$, Sukhi Sehmi $^5$, Samir Mehta $^5$, Neil Winkles $^5$, Peter Brocklehurst $^5$, Jonathan Mathers $^6$, Sue Jowett $^7$, Kate Jolly $^6$, Deirdre Lane $^8$, G Neil Thomas $^9$, Gregory Y H Lip $^{10,11}$, TREATS-AF Study Group

ABSTRACT

Introduction The burden of atrial fibrillation (AF) in Thailand is high and associated with increased morbidity, mortality and healthcare costs. Vitamin K antagonists (eg, warfarin), commonly used for stroke prevention in patients with AF in Thailand, are effective but are often suboptimally controlled. We aim to evaluate the impact of an SAMe-TT$_2$R$_2$ score-guided strategy and educational intervention compared to usual care on anticoagulation control expressed by the time in therapeutic range (TTR) at 12 months, in anticoagulant-naïve Thai patients with AF.

Methods and analysis Multicentre, open-label, parallel-group, randomised controlled trial conducted in Thailand among adult patients (age: 18 years) with AF who are anticoagulant naïve. Patients will be randomised to one of two groups; an SAMe-TT$_2$R$_2$ score-guided strategy with educational intervention and usual care versus usual care alone. The planned follow-up period is 12 months. The primary outcome is TTR at 12 months. Secondary outcomes include: (1) TTR at 6 months; (2) thromboembolic and bleeding events at 12 months; (3) composite major adverse cardiovascular events at 12 months; (4) change in patients’ knowledge of AF between baseline and 6 months and 12 months; (5) cost effectiveness; (6) quality of life at baseline, 6 months and 12 months using EQ-5D-5L (Thai version) and (7) patient satisfaction/perceptions of the TREAT intervention. An embedded qualitative study will assess patient perceptions of the TREAT intervention.

Ethics and dissemination The study has been approved by the Ethical Review Committee, Ministry of Public Health of Thailand, and registered in the Thai Clinical Trials Registry. The results of this trial will be submitted for publication in a peer-reviewed journal. Participants will be informed via a link to a preview of the publication. A lay summary will also be provided to all participants prior to publication.

Trial registration number TCTR20180711003.

INTRODUCTION

Atrial fibrillation (AF) is associated with decreased quality of life, and increased mortality and morbidity from stroke/thromboembolism. Incidence of AF has been...
increasing in developing countries, including Thailand, partly due to the rapid change of population dynamics towards an ageing society. The hospitalisation rate for Thai patients with AF was high (15.5 per 100,000 person-years), with a high mortality (44.0% after 72-month follow-up (average 46 months)). The high burden of AF in Thailand is also associated with similarly high healthcare costs.

Appropriate oral anticoagulation, either with a vitamin K antagonist (VKA, eg, warfarin) or with a non-VKA oral anticoagulants (NOAC), is essential for effective stroke prevention in patients with AF with one or more stroke risk factors. Despite the advantages of NOAC over VKA, the access of NOAC are generally limited due to cost. Hence, VKAs are widely used globally. In Thailand, warfarin is the default therapy for stroke prevention in AF but is often suboptimally managed due to the many inherent limitations associated with this drug, including diet, drug and alcohol interactions and difficulties with anticoagulation monitoring. Recent data from retrospective cohort studies, along with a nationwide registry, suggested that the average time in therapeutic range (TTR) among patients with AF in Thailand ranged from 50% to 55%. Those with suboptimal anticoagulation control, TTR <65%, had a twofold–threefold increased risk of stroke, major bleeding and death compared with those with TTR ≥65%. As a result, strategies to improve TTR control are clearly needed and would likely have a major impact on preventing these adverse events.

TTR is influenced by numerous modifiable and non-modifiable factors, but the more common clinical factors have been used to formulate the SAMe-TT2R2 score (table 1).

Several observational studies including those conducted in Asian populations, have demonstrated that an SAMe-TT2R2 value of >2 is predictive of poor TTR, all-cause mortality and the composite endpoint of thromboembolic events, major bleeding and mortality. By identifying those who are at risk of poor TTR, targeted efforts to improve TTR can be effectively provided to the vulnerable group. If TTR can be improved to >65%, VKAs can provide comparable efficacy and safety to that seen with NOACs. Prevoius studies have demonstrated that many patients with AF possess little knowledge about AF and do not understand the risks/benefits of OAC, and this may contribute to poor international normalised ratio (INR) control.

We have previously shown that an educational-behavioural intervention (TREAT, ISRCTN93952605) significantly improved TTR 6 months after warfarin initiation compared with usual care alone (78.5% vs 66.7%, respectively; p=0.01). Thus, a one-time structured educational-behavioural intervention among those predicted to be less likely to achieve good INR control may be a simple and cost-effective adjunct management strategy, which could help improve individual TTR. Increased patient understanding of disease and treatment, and a reduction of adverse events, may improve quality of life.

We, therefore, conducted a prospective individually randomised controlled trial (RCT) in anticoagulant-naive Thai patients with AF to assess whether the application of an SAMe-TT2R2 score-guided strategy and TREAT intervention plus usual care could improve anticoagulation control with warfarin (measured by percentage TTR) at 12 months (primary outcome) compared with usual care alone.

### Objectives

The primary objective of this study is to evaluate the impact of an SAMe-TT2R2 score-guided strategy and educational intervention (plus usual care) compared with usual care alone, on patient’s anticoagulation control with warfarin, as measured by the TTR at 12 months, in anticoagulant-naive Thai patients with AF. As secondary objectives, we aim to evaluate the impact of this intervention on patient knowledge, TTR at 6 months, thromboembolic and bleeding events and the composite major adverse cardiovascular events (MACE). We will also perform analysis to evaluate the cost effectiveness of the intervention and investigate patients’ satisfaction and acceptance of the TREAT intervention using a brief questionnaire and further in a qualitative sub-study.

### METHODS

#### Study design and setting

This is a multicentre, open-label, parallelled-group, RCT conducted among adult Thai patients (age: ≥18 years) with AF who are anticoagulant naïve. Patients who are eligible for stroke prevention according to the ESC Guidelines for the diagnosis and management of AF (men with CHA2DS2-VASc score ≥2; women with CHA2DS2-VASc score ≥3) will be randomised to one of two groups, either an SAMe-TT2R2 score-guided strategy (see table 1).
and educational intervention plus usual care versus usual care alone. The planned follow-up period is 12 months. Study sites are seven public hospitals across six provinces (Bangkok, Chiang Mai, Chiang Rai, Lampang, Khon Kaen and Nakhon Ratchasima) in Thailand. To promote generalisability of our findings, these seven hospitals are a combination of three university hospitals (Maharat Nakhon Chiang Mai Hospital, Siriraj Hospital, and Queen Sirikit Heart Centre of the Northeast) and four secondary/tertiary care hospitals (Maharat Nakhon Ratchasima Hospital, Chiang Rai Prachanukroh Hospital, Nakornping Hospital and Lampang Hospital). The study sites and investigators are listed in online supplemental appendix 1. The study protocol was approved by the Institutional Ethical Committee of each study site and by the Institutional Review Board (IRB) of the Ministry of Public Health, the Royal Government of Thailand (Central Research Committee (CREC) number: COA-CREC 007/2020) and registered with the Thai Clinical Trials Registry.

Participants
Newly diagnosed adult patients with AF identified and referred from cardiology, internal medicine, family medicine and general clinics at the hospitals and referrals from primary care will be eligible for enrolment into the study.

Eligibility criteria
Patients must meet all of the following inclusion criteria to be eligible for randomisation:
1. ≥18 years of age
2. Newly diagnosed patients with non-valvular AF.
3. ECG-documented AF
4. Warfarin eligible (men with CHA_2DS_2-VASc score ≥1; women with CHA_2DS_2-VASc score ≥2)
5. Warfarin naïve (no treatment with anticoagulation within the past 12 months; treatment may have started within the prior 28 days from randomization).
6. Able to comply with scheduled visits, treatment plan and laboratory tests
7. Able to give informed consent and comply with study protocol (with support of a carer)

Patients will be excluded from participation if they present with any of the following:
1. Any contraindication to oral anticoagulation
2. Prosthetic cardiac valve or significant valvular heart disease with an indication for heart surgery
3. Likelihood of intermittent or permanent discontinuation of warfarin during follow-up (eg, major surgery or post-AF ablation)
4. Known active malignancy with a life expectancy less than 5 years.
5. Diagnosed significant cognitive impairment preventing provision of informed consent and/or able to comply with the study protocol.
6. Any disease likely to cause death within 12 months.

The study was originally designed to enrol the patients within 5 days of warfarin treatment; however, the average referral time was 14 days. The trial steering committee agreed to extend the duration between starting warfarin and randomisation to 28 days to improve recruitment rate, external validity and generalisability of the trials. The amended study protocol was approved by the Institutional Ethical Committee of each study site and by the IRB of the Ministry of Public Health, the Royal Government of Thailand and updated in the Thai Clinical Trials Registry.

Randomisation
After participant eligibility has been confirmed and informed consent has been provided, the participant will be randomised into the trial. Randomisation will be done using a web-based platform with blinded allocation. Randomisation will be stratified based on centre, sex (male or female) and baseline SAMe-TT_2R_2 score (0–2, 3–5 and 6–8). Participants will be randomised at the level of the individual in a 1:1 ratio to either the SAMe-TT_2R_2 score-guided strategy and educational intervention plus usual care (intervention group) or usual care alone (figures 1 and 2). Group 1 is the usual care group using warfarin (control group). For Group 2, the patients are further divided into two groups. Group 2a are patients with an SAMe-TT_2R_2 score of 0–2 who will receive warfarin plus usual care. Group 2b are patients with an SAMe-TT_2R_2 score of ≥2 who will receive warfarin plus the TREAT education-behavioural intervention as an adjunct to their regular INR monitoring, to improve their TTR.

Trial intervention
As described previously, the TREAT intervention is a patient-centred intervention for patients with AF co-developed through the integration of theoretical and clinical frameworks, and patient feedback. This behaviour-change intervention package consists of an educational booklet, diary, worksheet and a DVD for reinforcement. The educational booklet covers AF causes and consequences, warfarin and its metabolism, stroke risk and risk of bleeding on treatment and lifestyle changes (diet, alcohol and lifestyle change). The patient DVD contains health professionals and ‘expert patient’ narratives that covers AF causes, consequences, side effects, treatment options, warfarin, INR monitoring, lifestyle changes, along with common psychological and physical barriers to anticoagulation that patients may experience. The patient worksheets include a simple self-calculation of stroke risk (CHA_2DS_2-VASc score), personal barriers to uptake of warfarin and discussion of personal goals for lifestyle changes. In addition, a self-monitoring diary, including diet, alcohol intake (in units), warfarin regimen and INR results is also provided.

To overcome the language barrier of the general Thai public toward English, the TREAT intervention was culturally adapted to fit the local context and then translated. Forward and backward translation by two bilingual experts was performed. A test run of the Thai version of the TREAT intervention was conducted among patients.
with AF with a range of educational ability (Thai literacy level is 94%) and age levels. Patient feedback was incorporated to improve the usability of the Thai-version TREAT intervention.

A training session was conducted to prepare all study site coordinators (pharmacists and nurses) on how to deliver the intervention effectively. To avoid contamination, those who provide the TREAT intervention and those who provide usual care will be two different groups of pharmacists and nurses. The intervention will be delivered within 4 weeks of initiating warfarin. Intervention fidelity will be ensured by direct observation of random sessions at each centre by the trainer. Patients in the usual care group will receive training on the OAC management from the anticoagulation clinic, and patient information about AF and need for warfarin by a healthcare professional using the standard warfarin education checklist.

**Patient and public involvement**

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research. The patients involved in the development of Thai version of the TREAT intervention.

**Outcome measures**

The primary outcome is TTR at 12 months. Secondary outcomes include (1) TTR at 6 months; (2) thromboembolic and bleeding events from at 12 months; (3) composite

---

**Figure 1** Study design and recruitment. Group 1: usual care using warfarin (control). Group 2: care pathway designated based on stratification of patients using the SAMe-TT2R2 score (warfarin plus usual care). Group 2 care pathways: Group 2a: SAMe-TT2R2 score 0–2 (warfarin plus usual care). NB: usual care would include management in the anticoagulation clinic, and patient information about AF and need for warfarin by a healthcare professional using the standard warfarin education checklist. Group 2b: SAMe-TT2R2 score >2 (warfarin plus intensive TREAT education-behavioural intervention as an adjunct to their regular INR monitoring to improve their TTR on warfarin). AF, atrial fibrillation; OAC, oral anticoagulants; TTR, time in therapeutic range.

**Figure 2** Timing of randomisation, study visits and follow-up.
MACE outcome of non-fatal MI, non-fatal stroke and cardiovascular death and all-cause mortality, in an exploratory analysis (combined and individually) at 12 months; (4) change in patients’ knowledge of AF from baseline to 6 months and 12 months; (5) cost effectiveness; (6) quality of life at baseline, 6 months and 12 months assessed using the 5-level EQ-5D version; (7) patient satisfaction/perceptions of the TREAT intervention. An embedded qualitative study will assess patient perceptions of the TREAT intervention.

Study procedures and schedules of assessment

Baseline SAMe-TTR$_2$ score will be calculated (table 1). All patients will receive warfarin, dose adjusted to achieve a target INR of 2.0–3.0. INR monitoring will be undertaken at routine intervals (as would occur in usual care) and will be recorded over a 12-month period. Patients will be randomised as described in figure 1, either to Group 1 (usual care) or Group 2 (intervention arm) for the trial is powered. Group 2 is a SAMe-TTR$_2$ score directed management group based on a: patients with AF likelihood of achieving and maintaining optimal TTR (SAMe-TTR$_2$ scores 0–2; Group 2a) and those likely to achieve poor TTR (SAMe-TTR$_2$ scores>2, Group 2b). From our prior data, approximately 15%–20% will likely enter Group 2a. The primary and secondary outcomes between Group 1 and Group 2 (together) will be compared. The schedule of assessment is presented in table 2. INR monitoring is independent of the intervention (ie, naturalistic) as we recognise that the improvement of TTR may be a result of more frequent monitoring. Patients in all groups will have their INR monitored as they would if they were not in the trial (by anticoagulation services which are separate from the trial and who are blinded to treatment allocation).

Data collection and management

Medical records of the participating hospitals serve as the source data, including clinical information and laboratory values, which are accessible and maintained in accordance to national standards and regulations. Outcome data will be extracted from participant’s clinical notes and laboratory reports into an electronic case record form (CRF). For long-term storage, clinical data will be electronically archived at Faculty of Medicine, Chiang Mai University, Thailand, as per the regulatory requirements for good clinical practice and in line with the Medical Research Council requirements and local policies.

The questionnaires will be completed by the patient. For those with literacy problems, the questionnaires will be read out to the participant, the participant will respond to each question and their responses will be recorded by the staff administering the questionnaires.

Trial data will be captured in a Research Electronic Data Capture (REDCap), secure SQL server database. An independent data monitoring committee (DMC), including both local and international experts, has been appointed and convened. Interim analyses of major outcome measures and safety data will be conducted and provided in strict...
confidence to the DMC. Any decision to stop the trial early will be based on the balance of efficacy and safety.

**Sample size and power calculations**

Most recent studies suggest that the mean TTR in Thai patients receiving warfarin is in the range of 50%–55%.11 Since an improvement of 10% in the mean TTR is likely to be clinically meaningful, we assume a 10% difference in 12-month TTR with 90% power and 5% significance level for our sample size calculation and using an SD of ‘26’ as observed in a previous Thai study to determine the sample size estimates. Hence, to detect a 10% mean difference in TTR at 12 months, using two-sided test, sample size for randomisation in a 1:1 ratio would be 288 or 144 per arm. Assuming and adjusting for a 10% attrition/loss to follow-up rate, a total sample size of 320 patients or 160 per arm is needed.

**Statistical analysis**

Continuous variables will be presented as mean (SD), or median (IQR), as appropriate; categorical variables will be reported as counts with percentages. Descriptive statistics will be presented for baseline demographic and clinical information. For all major outcomes, summary statistics and differences between groups (eg, mean differences and relative risks) will be presented, with CIs and p values from two-sided tests also given.

All analyses will be based on the intention-to-treat (ITT) principle. The primary comparison groups will be composed of those randomised to Group 1, usual care, versus those randomised to Group 2, the SAMe-TT.R2 score-guided strategy with the TREAT intervention (plus usual care). All outcomes will be adjusted for the stratification variables (centre, sex and baseline SAMe-TT.R2 score) where possible. Two-tailed p values <0.05 will be considered statistically significant. No adjustment for multiple comparisons will be made.

**Subgroup analysis**

Subgroup analyses will be conducted for the stratification variable sex only. All other stratification variables will be used only to ensure that the two groups are balanced in terms of these important variables. Subgroup analyses will be limited to the primary outcome only. Tests for statistical heterogeneity (eg, by including the treatment group by subgroup interaction parameter in the regression model) will be performed prior to any examination of effect estimates within subgroups. The results of subgroup analyses will be treated with caution and will be used for the purposes of hypothesis generation only.

**Missing data and sensitivity analyses**

Missing and ambiguous data will be queried using a data clarification system, and will focus on data required for trial outcome analysis and safety reporting. Every attempt will be made to collect full follow-up data on all study participants. A sensitivity analysis will be performed on the primary outcome measure only to examine the possible impact of any missing data for the primary outcome. This will include the use of multiple imputation using chained equations. Further sensitivity analysis will also be done if a substantial number of participants do not comply with randomised allocated group and so a per-protocol analysis may also be conducted. Any sensitivity analyses will not, irrespective of their differences, supplant the planned primary analyses.

**Interim analysis**

Interim analyses of safety and efficacy for presentation to the independent DMC will take place during the study. The committee will meet prior to study commencement to agree the manner and timing of such analyses. The analysis of the primary and major secondary outcomes and full assessment of safety (adverse events and serious adverse events) will be performed at annual intervals. Criteria for stopping or modifying the study based on this information will be ratified by the DMC.

**Planned final analyses**

The final analysis for the study will occur once the last randomised participant has completed the 12-month follow-up and any corresponding outcome data have been entered onto the study database and validated as being ready for analysis.

**Withdrawal**

Patients may withdraw consent from the study at any time. Patients may also withdraw from trial treatment but continue with study follow-up and data collection as per the protocol. If the withdrawal is initiated by a healthcare professional, full details for the reason for withdrawal will be recorded on the case report forms. In all other cases, a simple statement reflecting the patient’s preference will be noted. The patients who are switched to NOACs will be followed for clinical events. The INR data will be collected to the end of warfarin treatment for the TTR calculation and analysis as ITT analysis.

**Analysis of outcome measures**

**Primary outcome**

The primary outcome is the TTR at 12 months and differences in TTR between the intervention and usual care groups will be examined using a linear regression model. Results will be presented as mean difference and 95% CI. A key assumption for this analysis is that the data will be normally distributed; this assumption will be examined visually based on the residuals from the fitted model. If data are deemed not to be normally distributed, then the Mann-Whitney U test will be used for analysis.

**Secondary outcomes**

The secondary endpoints for the trial includes continuous, categorical and time-to-event data items. Any secondary endpoints that are continuous in nature will be analysed in the same way as described for the primary outcome. For dichotomous secondary endpoints, the proportion of participants and percentages will be compared between arms using a log-binomial model.
Relative risks and 95% CIs will be calculated. For any time-to-event outcomes these will be compared between treatment arms by using survival analysis methods. Cox proportional hazards model will be used and treatment effects will be expressed as HRs with 95% CIs. Kaplan-Meier survival curves will be constructed for visual presentation of time-to-event comparisons.

Qualitative study
Qualitative data will be obtained directly from patient interviews and interviews with healthcare professionals delivering the intervention as part of an embedded qualitative substudy. A purposive sample of 10–15 participants from the intervention arm will take part in one-to-one semi-structured interviews with a qualitative researcher, at two time-points (within 4 weeks of the intervention and at 6-months follow-up). Interviews will explore participants’ experience of AF; of receiving the TREAT intervention; their perspectives on the utility of different interventions components; as well as behavioural modifications resulting from the intervention. Staff delivering the intervention at each study site will also be interviewed to understand their perceptions of the TREAT intervention and their experience of delivering it to patients. A thematic analysis of interview content will be informed by the framework analytic approach. Audio-recorded interviews will be translated and transcribed into English in order to facilitate team-based analysis by Thai and English research team members.31

Health economics analysis
The economic evaluation will determine the cost effectiveness of the intensive educational intervention versus usual care. The evaluation will take the form of an incremental cost–utility analysis to estimate cost per quality adjusted life year (QALY) over 12-months follow-up from a Thailand health service perspective. If differences in TTR are achieved in the trial, a longer-term Markov model-based cost per QALY analysis will be also undertaken.

Data collection
Data will be collected on healthcare utilisation required for the intervention, warfarin therapy and monitoring, and healthcare visits, hospitalisations, investigations and medication related to thromboembolism, bleeding and management of AF. Information will be collected at the 6-month and 12-month patient visits from trial CRFs and hospital records. Additional costs, such as those associated with transportation to the hospital, will be collected from the patients. The EQ-5D-5L (Thai version) questionnaire will be administered to participants at baseline, 6 months and 12 months to estimate QALYs.

Data analysis
Unit costs from standard Thai sources will be applied to all healthcare resource use items, and mean resource use (for each category of healthcare usage) and mean total costs will be calculated for both trial arms. The current Thailand’s value set will be applied to patient EQ-5D-5L responses to obtain utility scores and QALYs will be calculated using the area under the curve approach. Multiple imputation will be used to impute all missing values for the EQ-5D-5L and total cost estimates for non-responders. As cost and QALY data are likely to have a skewed distribution, a non-parametric comparison of means (using bootstrapping) will be undertaken. A cost–consequence analysis will initially be reported, describing all the important results relating to resource use, costs and consequences. Incremental cost-effectiveness and cost–utility analyses will then be undertaken to estimate the incremental cost per QALY gained at 12 months, with adjustment for baseline covariates. The robustness of the results will be explored using sensitivity analysis. Cost-effectiveness acceptability curves (CEACs) will also be produced to reflect the probability that the intervention will be cost effective at different cost per QALY willingness to pay thresholds.

Model-based analysis
If the trial data show a benefit in TTR due to the intervention, trial results will be extrapolated using a Markov model-based cost per QALY. This model will take into account the long-term impact of anticoagulant control on thromboembolism and bleeding over the patient’s lifetime, with costs and outcomes discounted at 3%. The model structure will be informed by previously published modelling studies and expert opinion. Extensive deterministic sensitivity analysis using predefined ranges will be undertaken to explore which model parameters have most impact on cost effectiveness. Parameter estimates will be incorporated into the model as distributions to allow for a probabilistic sensitivity analysis, with CEACs constructed to assess the probability of cost effectiveness at different cost per QALY willingness to pay thresholds.

Trial status
The study protocol V2.1 dated 19 August 2019 was approved by the Institutional Ethical Committee of each study site and by the IRB of the Ministry of Public Health, the Royal Government of Thailand (CREC number: COA-CREC 007/2020) and the study protocol had amended and approved at V3.0 dated 9 June 2020. The recruitment of participants started in 31 January 2020. Last patient recruitment is expected in May 2021. Data collection is expected to be completed in December 2021.

Dissemination
Results of this trial will be submitted for publication in a peer-reviewed journal. The manuscript will be prepared by the principal investigators or their delegates and authorship will be determined by the trial publication policy. Participants will be informed of the outcome of the trial via a link to a preview of the publication. A lay summary will also be provided via email or posted to participants prior to publication.

Author affiliations
1 Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
2 Center for Medical Excellence, Faculty of Medicine, Chiang Mai, Thailand
Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
Department of Public Health and Epidemiology, Institute of Applied Health Research, University of Birmingham, Birmingham, UK
Department of Cardiovascular Health, Faculty of Health and Life Sciences, Health Economics Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK
Department of Clinical Medicine, Aalborg Universitet, Aalborg, Denmark

Contributors
Wongtheptien, Thanyaluck Chotayaporn, Natrawee Bureekam, Bancha Sankyo outside the submitted work.

Acknowledgements
We acknowledge the assistance and facilities provided by the Medical Research Council, the UK (grant reference number: MR/R020892/1) and WW: reports speaker fees from Bayer, Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo.

Funding
This study is supported by the Newton Fund through the collaboration of the Medical Research Council, the UK (grant reference number: MR/R020892/1) and the Thai Research Fund, Thailand (grant reference number: DBG61800009).

Competing interests
All other authors have no actual or potential conflict of interest capable of influencing judgment on the part of any author on this work. AP and WW: reports speaker fees from Bayer, Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo outside the submitted work. DL: reports investigator-initiated educational grants from Bristol-Myers Squibb (BMS); speaker fees for Boehringer Ingelheim, Bayer and BMS/Pfizer; and consultancy for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo, all outside of the submitted work. GL: reports consultancy and speaker fees for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo. No fees are received personally.

Patient and public involvement
Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication
Not applicable.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available upon reasonable request.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID ids
Arintaya Phrommintikul http://orcid.org/0000-0003-3986-1951
Jonathan Mathers http://orcid.org/0000-0001-6651-6286
Deirdre Lane http://orcid.org/0000-0002-5604-9378
G Neil Thomas http://orcid.org/0000-0002-2777-1847
Gregory Y H Lip http://orcid.org/0000-0002-7566-1626

REFERENCES
1 Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS). Eur Heart J 2021;42:373–498.
2 Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: chest guideline and expert panel report. Chest 2018;154:1121–201.
3 Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2014;129:837–47.
4 Phrommintikul A, Dethunantar P, Prasertwitayakij N, et al. Prevalence of atrial fibrillation in Thai elderly. J Geriatr Cardiol 2016;13:270–3.
5 Apisayawat S, Tangcharoen T, Wisarattapong T, et al. CHA2DS-VASC scores predict mortality after hospitalization for atrial fibrillation. Int J Cardiol 2015;185:293–6.
6 Ng NS, Nathisuwan S, Phrommintikul A, et al. Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand. Thromb Res 2020;185:63–71.
7 Kirchhof P, Benussi S, Cotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with eacts. Eur J Cardiothorac Surg 2016;50:e1–88.
8 Krittayapong R, Phrommintikul A, Ngamjanyaporn P, et al. Rate of anticoagulant use, and factors associated with not prescribing anticoagulant in older Thai adults with non-valvular atrial fibrillation: a multicenter registry. J Geriatr Cardiol 2019;16:242–50.
9 Tse H-F, Wang Y-J, Ahmed Ali-Abdullah M, et al. Stroke prevention in atrial fibrillation—an Asian stroke perspective. Heart Rhythm 2013;10:1082–8.
10 Saokaw S, Sapoo U, Nathisuwan S, et al. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. Int J Clin Pharm 2012;34:105–12.
11 Pirski W, Rattanavipanon W, Saejarwet W, et al. Incidence, risk factors, and outcomes of warfarin-associated major bleeding in Thai population. Pharmacoepidemiol Drug Saf 2019;28:942–50.
12 Krittayapong R, Chantararat T, Rojaikepamai R, et al. Poor time in therapeutic range control is associated with adverse clinical outcomes in patients with Non-Valvular atrial fibrillation: a report from the nationwide cool-AF registry. J Clin Med 2020;9. doi:10.3390/jcm9061698. [Epub ahead of print: 02 06 2020].
13 Zulkifli H, Lip GYH, Lane DA. Use of the same-TT-R score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review. Heart Rhythm 2016;13:815–23.
14 Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the same-TT-R score. Chest 2013;144:1555–63.
15 Lip GYH, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAmE-TT-R score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014;146:719–26.
16 Bernatis N, Ching CK, Chen L, et al. The Sex, age, medical history, treatment, tobacco use, race risk (same TT2R2) score predicts warfarin control in a Singaporean population. J Stroke Cerebrovasc Dis 2017:64–9.
17 Chan PH, Hai JJ, Chan EW, et al. Use of the same-TT2R2 score to predict good anticoagulation control with warfarin in Chinese patients with atrial fibrillation: relationship to ischemic stroke incidence. PLoS One 2016;11:e0150674.
18 Sjögren V, Gryzmalia-Lubanski B, Renlund H, et al. Safety and efficacy of well managed warfarin. a report from the Swedish quality register Auricula. Thromb Res 2015;115:137–44.
19 Björk F, Renlund H, Lip GYH, et al. Outcomes in a warfarin-treated population with atrial fibrillation. JAMA Cardiol 2016;1:172–80.
20 Lip GYH, Kamath S, Jafari M, et al. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham atrial fibrillation project. Stroke 2002;33:236–42.
21 Lane DA, Aguina G, Blomström-Lundqvist C, et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European heart rhythm association (EHRA) consensus document endorsed by the heart rhythm Society (HRS), Asia Pacific heart rhythm Society (APHRS), and sociedad latinoamericana de estimulación cardíaca y electrophisiología (SOALEAC). Europace 2015;17:1747–69.
22 Frankel DS, Parker SE, Rosenfeld LE, et al. HRS/NSA 2014 survey of atrial fibrillation and stroke: gaps in knowledge and perspective, opportunities for improvement. J Stroke Cerebrovasc Dis 2015;24:1691–700.
23 McCabe PJ, Schad S, Hampton A, et al. Knowledge and self-management behaviors of patients with recently detected atrial fibrillation. Heart Lung 2008;37:79–90.
24 Destrège L, Engelhardt L, Raymaekers Z, et al. Knowledge gaps in patients with atrial fibrillation revealed by a new validated knowledge questionnaire. Int J Cardiol 2016;223:906–14.
25 Lane DA, Ponsford J, Shelley A, et al. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. the West Birmingham atrial fibrillation project. *Int J Cardiol* 2006;110:354–8.

26 Clarkesmith DE, Pattison HM, Lip GYH, et al. Educational intervention improves anticoagulation control in atrial fibrillation patients: the treat randomised trial. *PLoS One* 2013;8:e74037.

27 Clarkesmith DE, Pattison HM, Borg Xuereb C, et al. Developing a complex educational-behavioural intervention: the treat intervention for patients with atrial fibrillation. *Healthcare* 2016;4. doi:10.3390/healthcare4010010. [Epub ahead of print: 14 01 2016].

28 Smith DE, Xuereb CB, Pattison HM, et al. Trial of an educational intervention on patients’ knowledge of atrial fibrillation and anticoagulant therapy, Inr control, and outcome of treatment with warfarin (treat). *BMC Cardiovasc Disord* 2010;10:21.

29 Pattanaphesaj J, Thavorncharoensap M, Ramos-Goiño JM, et al. The EQ-SD-5L valuation study in Thailand. *Expert Rev Pharmacoecon Outcomes Res* 2018;18:551–8.

30 Sonsarjijit N, Sakkhong P. Reliability and validity of the Thai version of EQ-5D-5L questionnaire on patients with chronic disease. *Chula Med J* 2015;59:489–501 https://www.semanticscholar.org/paper/Reliability-and-validity-of-the-Thai-version-of-D-5-Sakkhong/de801256c2577dd899a4200991e02054125bab6d

31 Gale NK, Heath G, Cameron E, et al. Using the framework method for the analysis of qualitative data in mult-disciplinary health research. *BMC Med Res Methodol* 2013;13:117.